Next Article in Journal
Development, Characterization, and Stability Evaluation of the Anti-Cellulite Emgel Containing Herbal Extracts and Essential Oils
Next Article in Special Issue
Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates
Previous Article in Journal
JAK-STAT Pathway Regulation of Intestinal Permeability: Pathogenic Roles and Therapeutic Opportunities in Inflammatory Bowel Disease
Previous Article in Special Issue
Internalisation and Biological Activity of Nucleic Acids Delivering Cell-Penetrating Peptide Nanoparticles Is Controlled by the Biomolecular Corona
 
 
Article

Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids

1
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Plaza, Houston, TX 77030, USA
2
National School of Tropical Medicine and Department of Pediatrics, Section of Tropical Medicine, Baylor College of Medicine, One Plaza, Houston, TX 77030, USA
3
Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Co-senior authors.
Academic Editor: Hamidreza Montazeri Aliabadi
Pharmaceuticals 2021, 14(9), 841; https://doi.org/10.3390/ph14090841
Received: 23 June 2021 / Revised: 14 August 2021 / Accepted: 23 August 2021 / Published: 25 August 2021
We previously reported a new polymer, lactic-co-glycolic acid-polyethylenimine (LGA-PEI), as an improved nanoparticle (NP) delivery for therapeutic nucleic acids (TNAs). Here, we further developed two antibody (Ab)-conjugated LGA-PEI NP technologies for active-targeting delivery of TNAs. LGA-PEI was covalently conjugated with a single-chain variable fragment antibody (scFv) against mesothelin (MSLN), a biomarker for pancreatic cancer (PC), or a special Ab fragment crystallizable region-binding peptide (FcBP), which binds to any full Ab (IgG). TNAs used in the current study included tumor suppressor microRNA mimics (miR-198 and miR-520h) and non-coding RNA X-inactive specific transcript (XIST) fragments; green fluorescence protein gene (GFP plasmid DNA) was also used as an example of plasmid DNA. MSLN scFv-LGA-PEI NPs with TNAs significantly improved their binding and internalization in PC cells with high expression of MSLN in vitro and in vivo. Anti-epidermal growth factor receptor (EGFR) monoclonal Ab (Cetuximab) binding to FcBP-LGA-PEI showed active-targeting delivery of TNAs to EGFR-expressing PC cells. View Full-Text
Keywords: polyethylenimine; LGA-PEI polymer; nanoparticle; active targeting delivery; therapeutic nucleic acid polyethylenimine; LGA-PEI polymer; nanoparticle; active targeting delivery; therapeutic nucleic acid
Show Figures

Graphical abstract

MDPI and ACS Style

Lü, J.-M.; Liang, Z.; Liu, D.; Zhan, B.; Yao, Q.; Chen, C. Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids. Pharmaceuticals 2021, 14, 841. https://doi.org/10.3390/ph14090841

AMA Style

Lü J-M, Liang Z, Liu D, Zhan B, Yao Q, Chen C. Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids. Pharmaceuticals. 2021; 14(9):841. https://doi.org/10.3390/ph14090841

Chicago/Turabian Style

Lü, Jian-Ming, Zhengdong Liang, Dongliang Liu, Bin Zhan, Qizhi Yao, and Changyi Chen. 2021. "Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids" Pharmaceuticals 14, no. 9: 841. https://doi.org/10.3390/ph14090841

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop